Lundbeck disagrees with the Statement of Objections issued by the European Commission
25 July 2012 | By H. Lundbeck A/S
The European Commission has issued a Statement of Objections to Lundbeck...
List view / Grid view
25 July 2012 | By H. Lundbeck A/S
The European Commission has issued a Statement of Objections to Lundbeck...
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
25 July 2012 | By Merck
Merck announced the publication of a study...
24 July 2012 | By Pegasus
The first study to compare the 8% capsaicin patch with pregabalin...
24 July 2012 | By Merck
Merck remains committed to advancing treatment for people with HIV...
24 July 2012 | By Gilead Sciences, Inc.
Full clinical trial results from a pivotal Phase 3 study...
23 July 2012 | By Pfizer
Co-primary clinical endpoints not met in study of patients with Alzheimer’s disease who carry the ApoE4 genotype...
23 July 2012 | By Roche
Almost four times as many patients achieve remission with RoActemra (tocilizumab) compared to Humira (adalimumab)...
23 July 2012 | By Boehringer Ingelheim
FX125L is a small molecule...
22 July 2012 | By Eli Lilly and Company
Results from a pharmacokinetic study...
20 July 2012 | By Pfizer
“The CHMP’s positive opinion brings us a step closer..."
20 July 2012 | By Novartis
The US FDA has approved Afinitor® tablets...
20 July 2012 | By Sanofi
ODYSSEY will comprise over 10 clinical trials...
19 July 2012 | By Catalent Pharma Solutions
Why single use is ideal for cell line development and bio-manufacturing...
19 July 2012 | By Pfizer
“The Court’s decision recognizes the infringement & validity of our LYRICA® patents..."